<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816604</url>
  </required_header>
  <id_info>
    <org_study_id>GB002-2102</org_study_id>
    <nct_id>NCT04816604</nct_id>
  </id_info>
  <brief_title>Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gossamer Bio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in&#xD;
      subjects who previously participated in a GB002 PAH study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From first dose of study drug up to 76 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time on the Six-Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline, up to 76 weeks</time_frame>
    <description>Change in the distance achieved on the 6MWT (Δ6MWT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>GB002 (seralutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB002 (seralutinib) inhaled orally twice per day (BID) over 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB002 (seralutinib)</intervention_name>
    <description>Capsule containing GB002 (seralutinib)</description>
    <arm_group_label>GB002 (seralutinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Generic Dry Powder Inhaler</intervention_name>
    <description>Generic dry powder inhaler for GB002 (seralutinib) delivery</description>
    <arm_group_label>GB002 (seralutinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Type of Subject and Disease Characteristics&#xD;
&#xD;
          1. Subjects must have completed a prior GB002 PAH study and, in the opinion of the&#xD;
             Investigator and Sponsor, have been compliant with study procedures and have completed&#xD;
             treatment with IP through parent study end-of-treatment (EOT) visit.&#xD;
&#xD;
          2. Treatment with standard of care PAH disease-specific background therapies (stable&#xD;
             dose).&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          3. Review and signature of an IRB-approved informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Persistent and clinically significant systemic hypertension or hypotension.&#xD;
&#xD;
          2. Interval history of newly developed left-sided heart disease.&#xD;
&#xD;
             a. History of severe and untreated obstructive sleep apnea.&#xD;
&#xD;
          3. Potentially life-threatening cardiac arrhythmia with an ongoing risk.&#xD;
&#xD;
          4. Uncontrolled bacterial, viral, or fungal infections which require systemic therapy.&#xD;
&#xD;
          5. Other severe acute or chronic medical or laboratory abnormality that may increase the&#xD;
             risk associated with study participation or GB002 administration or may interfere with&#xD;
             the interpretation of study results and, in the judgment of the Investigator, would&#xD;
             make the subject inappropriate for entry into this study.&#xD;
&#xD;
          6. History of portopulmonary hypertension or portal hypertension classified as Child-Pugh&#xD;
             Class A or higher.&#xD;
&#xD;
          7. Subjects with a history of severe milk protein allergy. In addition, subjects with&#xD;
             known intolerance or hypersensitivity to lactose who, in the opinion of the&#xD;
             investigator, may experience severe symptoms following the ingestion of lactose.&#xD;
&#xD;
          8. Current use of inhaled tobacco and/or inhaled marijuana. Ingestible or topical&#xD;
             marijuana is allowed, per local restrictions and regulations.&#xD;
&#xD;
          9. Documented history of alcohol abuse and/or history of utilizing drugs of abuse&#xD;
             (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).&#xD;
&#xD;
         10. Have any other condition or reason that, in the opinion of the Investigator and/or the&#xD;
             Sponsor's Medical Monitor (or designee), would prohibit the subject from participating&#xD;
             in the study.&#xD;
&#xD;
             Diagnostic Assessments&#xD;
&#xD;
         11. Chronic renal insufficiency&#xD;
&#xD;
         12. Hemoglobin (Hgb) concentration &lt;8.5 g/dL.&#xD;
&#xD;
         13. Absolute neutrophil count (ANC) &lt; 1x 10^9/L.&#xD;
&#xD;
         14. Platelet count &lt;50 x 10^9/L.&#xD;
&#xD;
             Prior Therapy&#xD;
&#xD;
         15. Use of inhaled prostanoids.&#xD;
&#xD;
         16. Chronic use of oral anticoagulants (ie, coumadin or novel oral anticoagulant [NOAC]).&#xD;
&#xD;
         17. Chronic use of any prohibited medication.&#xD;
&#xD;
        NOTE: Additional inclusion/exclusion criteria may apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Aranda</last_name>
    <role>Study Director</role>
    <affiliation>Gossamer Bio Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GB002, Inc.</last_name>
    <phone>1-866-668-4083</phone>
    <email>ClinicalTrials@gossamerbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Pulmonary Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seralutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

